Complex Generics Drought Could Make Teva Stock ‘Relatively Rudderless’
Israeli Firm Aiming For Gx Forteo, Xulane To Cross The Line In 2023
The market has responded to Teva’s newly released 2023 financial guidance, with lingering questions over its ability to hit its forecasts amid a continued dearth of complex generics and further investments in Teva’s pipeline.
